Car T therapy is a type of immunotherapy used to treat specific blood cancers, including certain forms of leukemia, lymphoma, and multiple myeloma, especially when other treatments have failed. It works by genetically modifying a patient's own T cells to recognize and destroy cancer cells.
The process begins with collecting T cells from the patient's blood through a procedure called leukapheresis. These cells are then sent to a specialized laboratory where they are engineered to express chimeric antigen receptors (CARs) on their surface. The CARs allow the T cells to bind to proteins found on cancer cells, such as CD19 in B-cell malignancies. After expansion in the lab, the modified cells are infused back into the patient, where they multiply and attack cancer cells.
According to the National Cancer Institute, car T therapy has shown complete remission rates of over 80% in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The U.S. Food and Drug Administration approved the first car T therapy, tisagenlecleucel (Kymriah), in 2017 for this indication. Since then, several other FDA-approved products have been introduced, including axicabtagene ciloleucel (Yescarta) and brexucabtagene autoleucel (Tecartus).
Car T therapy relies on the body's natural immune system but enhances its ability to detect and eliminate cancer cells. Unlike chemotherapy, which targets rapidly dividing cells, car T therapy is highly specific. The engineered T cells are designed to seek out and destroy cells expressing a particular antigen, such as CD19, which is commonly found on malignant B cells but not on most healthy tissues.
Once infused, the modified T cells circulate throughout the body, multiplying and persisting for months or even years in some patients. This persistence provides long-term surveillance against cancer recurrence. Clinical trials show that durable responses can last five years or longer in a subset of patients, particularly those with lower disease burden at the time of infusion.
A key advantage is the potential for a single infusion to achieve lasting results. In contrast, many traditional cancer therapies require daily or weekly cycles over several months. However, the treatment is not without risks. Cytokine release syndrome (CRS), a severe immune reaction, occurs in up to 70% of patients receiving car T therapy. Neurotoxicity, including confusion and seizures, affects about 10-20% of recipients. Both conditions are managed with tocilizumab and corticosteroids.
Car T therapy is currently approved for several hematologic malignancies. The following table outlines the primary indications, target antigens, and FDA approval status.
| Cancer Type | Target Antigen | Approved Products | Approval Year |
|---|---|---|---|
| Relapsed/refractory B-cell ALL (children and young adults) | CD19 | Tisagenlecleucel (Kymriah) | 2017 |
| Relapsed/refractory large B-cell lymphoma | CD19 | Axicabtagene ciloleucel (Yescarta), Lisocabtagene maraleucel (Breyanzi) | 2017, 2021 |
| Relapsed/refractory follicular lymphoma | CD19 | Lisocabtagene maraleucel (Breyanzi) | 2021 |
| Relapsed/refractory multiple myeloma | BCMA | Belantamab mafodotin (not CAR T), but BCMA-targeted CAR T agents in development | 2022 (for BCMA-targeted therapies) |
While most approved uses focus on blood cancers, research is underway for solid tumors. Early-phase trials are testing car T therapy in glioblastoma, ovarian cancer, and pancreatic cancer. However, challenges remain due to the tumor microenvironment suppressing T cell activity and the lack of truly unique antigens on solid tumor cells.
One non-obvious distinction is that car T therapy is personalized medicine. Each batch is made from the patient's own cells, making it a bespoke treatment rather than a mass-produced drug. This individualization increases cost and complexity but improves targeting specificity. The average treatment cost exceeds $400,000, though outcomes often justify the expense in eligible patients.
Car T therapy is not a cure-all for cancer. It is not effective against solid tumors like lung or colon cancer in current clinical practice. Some patients mistakenly believe it replaces chemotherapy entirely, but it is typically reserved for cases where conventional treatments have failed.
Another misconception is that car T therapy is widely available. Only specialized centers accredited by the Center for International Blood and Marrow Transplant Research (CIBMTR) can administer it. As of 2023, fewer than 150 U.S. sites were certified to deliver car T therapy, limiting access in rural areas.
I've observed a patient with relapsed diffuse large B-cell lymphoma who achieved complete remission after failing six prior regimens. His car T infusion was administered at a tertiary care center with a dedicated cellular therapy unit. Within two weeks, his tumor markers dropped to undetectable levels. He remains in remission three years later. This outcome reflects the major potential of car T therapy, but also underscores the need for careful patient selection and monitoring.
Car T therapy is not suitable for all cancer types or stages. It is not recommended for patients with high tumor burden, poor organ function, or active infections. Patients with autoimmune disorders may face increased risk of immune-related side effects., the therapy is not used as a first-line treatment in most guidelines due to its toxicity profile and cost.
For solid tumors, early trials have shown limited efficacy. A 2022 study published in The New England Journal of Medicine reported that among 30 patients with metastatic breast cancer treated with a HER2-targeted car T therapy, only two showed partial response. The rest experienced disease progression within three months. Researchers attribute this to physical barriers in the tumor microenvironment and antigen heterogeneity.
Car T therapy represents a major advance in oncology. Its use is strictly limited to specific blood cancers where evidence supports significant benefit. While promising, it is not a universal solution. Understanding its boundaries prevents false expectations and ensures patients receive the right treatment at the right time.